A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Tegoprazan (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors CJ HealthCare
  • Most Recent Events

    • 28 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 28 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2017.
    • 20 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top